Comparative safety analysis of baloxavir marboxil and oseltamivir based on the FAERS database.
Expert Opinion on Drug Safety April 24, 2025 Yingqiu Tu, Xin Lai, Qing Wan et al. 2 citations
This study aimed to analyze adverse drug events (ADEs) of oseltamivir or baloxavir marboxil monotherapy using the Food and Drug Administration Adverse Event Reporting System (FAERS) database, providing a valuable reference for clinical drug safety. FAERS data for oseltamivir and baloxavir marboxil from their market approval in the United States until the third quarter of 2023 were retrieved....